"AI for Obesity Treatment" Samjin Pharmaceutical, Collaborates with Namu ICT

[Financial News] Samjin Pharmaceutical announced on the 21st that it has signed a joint research agreement with Namu ICT for a new obesity treatment drug using an AI platform.
Under this agreement, Samjin Pharmaceutical will oversee △target proposal and indication selection △synthesis and efficacy evaluation of candidate substances △formulation, preclinical, clinical development, approval, and commercialization. Namu ICT will utilize its AI platform to handle △new structure design △candidate substance optimization △prediction of physicochemical properties, drug metabolism and pharmacokinetics (DMPK), and target binding ability.
The two companies plan to develop an innovative new drug with a differentiated mechanism that has weight loss, muscle preservation, and long-term safety.
Yeom Min-seon, Director of Namu ICT, said, "Through Dainon, we can accelerate the discovery and optimization of obesity treatments," and "will lead the development of innovative new drugs with global competitiveness."
Lee Su-min, Head of Research Center at Samjin Pharmaceutical, emphasized, "This joint research will expedite the development of a differentiated new mechanism obesity treatment," and "will achieve meaningful new drug development results in the global market."

kaya@fnnews.com Choi Hye-rim Reporter